Regencell Bioscience Holdings Ltd

NASDAQ RGC

Download Data

Regencell Bioscience Holdings Ltd Price to Book Ratio (P/B) on June 03, 2024: 4.96

Regencell Bioscience Holdings Ltd Price to Book Ratio (P/B) is 4.96 on June 03, 2024, a -79.05% change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.
  • Regencell Bioscience Holdings Ltd 52-week high Price to Book Ratio (P/B) is 24.21 on July 07, 2023, which is 387.66% above the current Price to Book Ratio (P/B).
  • Regencell Bioscience Holdings Ltd 52-week low Price to Book Ratio (P/B) is 3.73 on March 26, 2024, which is -24.84% below the current Price to Book Ratio (P/B).
  • Regencell Bioscience Holdings Ltd average Price to Book Ratio (P/B) for the last 52 weeks is 12.65.
NASDAQ: RGC

Regencell Bioscience Holdings Ltd

CEO Mr. Yat-Gai Au
IPO Date July 16, 2021
Location Hong Kong
Headquarters First Commercial Building, Causeway Bay, Hong Kong
Employees 12
Sector Healthcare
Industry Drug manufacturers - specialty & generic
Description

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder, as well as infectious diseases. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Similar companies

EGRX

Eagle Pharmaceuticals Inc

NA

NA

PAHC

Phibro Animal Health Corporation

NA

NA

PROC

Procaps Group SA

NA

NA

StockViz Staff

September 16, 2024

Any question? Send us an email